Search Site
  • 0
    My Cart

    Click Here to Find How Many Items You Have Added:)

    image loader

    Adding item(s) to cart......

Home >> Signaling Pathways >> Chromatin/Epigenetics

Chromatin/Epigenetics

Chromatin/Epigenetics

Epigenetics

Epigenetics means above genetics. It determines how much and whether a gene is expressed without changing DNA sequences. Epigenetic regulations include, 1. DNA methylation: the addition of methyl group to DNA, converting cytosine to 5-methylcytosine, mostly at CpG sites; 2. Histone modifications: posttranslational modificationEpigeneticss of histone proteins including acetylation, methylation, ubiquitylation, phosphorylation and sumoylation; 3. miRNAs: non-coding microRNA downregulating gene expression; 4. Prions: infectious proteins viewed as epigenetic agents capable of inducing a phenotype without changing the genome.

Targets for  Chromatin/Epigenetics

Products for  Chromatin/Epigenetics

  1. Cat.No. Product Name Information
  2. GC65326 GNE-375 GNE-375 is a potent and highly selective BRD9 inhibitor with an IC50 of 5 nM. GNE-375 shows >100-fold selective for BRD9 over BRD4, TAF1, and CECR2. GNE-375 decreases BRD9 binding to chromatin. GNE-375 Chemical Structure
  3. GC32081 GNE-781 GNE-781 is an orally active, highly potent and selective CBP inhibitor with an IC50 of 0.94 nM in TR-FRET assay. GNE-781 also inhibits BRET and BRD4(1) with IC50s of 6.2 nM and 5100 nM, respectively. GNE-781 displays antitumor activity in an MOLM-16 AML xenograft model. GNE-781 Chemical Structure
  4. GC33253 GNE-955 GNE-955 is a potent and orally active pan Pim kinase inhibitor with Kis of 0.018, 0.11, 0.08 nM for Pim1, Pim2, Pim3, respectively. GNE-955 Chemical Structure
  5. GC40918 Gramicidin A Gramicidin A is a peptide component of gramicidin, an antibiotic mixture originally isolated from B. Gramicidin A Chemical Structure
  6. GC46152 GS-441524 An antiviral nucleoside analog GS-441524 Chemical Structure
  7. GC33204 GS-626510 GS-626510 is a potent, and orally active BET family bromodomains inhibitor, with Kd values of 0.59-3.2 nM for BRD2/3/4, with IC50 values of 83 nM and 78 nM foe BD1 and BD2, respectively. GS-626510 Chemical Structure
  8. GC31731 GSK 4027 A PCAF/GCN5 bromodomain inhibitor GSK 4027 Chemical Structure
  9. GC10524 GSK 525768A GSK 525768A Chemical Structure
  10. GC50697 GSK 591 dihydrochloride GSK 591 dihydrochloride Chemical Structure
  11. GC12440 GSK 5959 BRPF1 bromodomain inhibitor GSK 5959 Chemical Structure
  12. GC34314 GSK 690 Hydrochloride GSK 690 (Hydrochloride) is a reversible inhibitor of lysine specific demethylase 1 (LSD1), with a Kd value of 9 nM and a biochemical IC50 of 37 nM. GSK 690 Hydrochloride Chemical Structure
  13. GC50378 GSK 9311 hydrochloride Negative control for GSK 6853 GSK 9311 hydrochloride Chemical Structure
  14. GC10617 GSK J1 A dual inhibitor of JMJD3 and UTX GSK J1 Chemical Structure
  15. GC13086 GSK J2 inactive control of GSK J1, JMJD3 (KDM6B) and UTX (KDM6A) inhibitor GSK J2 Chemical Structure
  16. GC12997 GSK J4 free base GSK J4 free base is a potent dual inhibitor of H3K27me3/me2-demethylases JMJD3/KDM6B and UTX/KDM6A with IC50s of 8.6 and 6.6 μM, respectively. GSK J4 free base inhibits LPS-induced TNF-α production in human primary macrophages with an IC50 of 9 μM. GSK J4 is a cell permeable prodrug of GSK-J1. GSK J4 free base induces endoplasmic reticulum stress-related apoptosis. GSK J4 free base Chemical Structure
  17. GC15497 GSK J4 HCl Prodrug of a selective H3K27 histone demethylase inhibitor GSK J4 HCl Chemical Structure
  18. GC17118 GSK J5

    inactive isomer of GSK J4, KDM inhibitor

     GSK J5 Chemical Structure
  19. GC63483 GSK-3685032 GSK-3685032 is a non-time-dependent, noncovalently, first-in-class reversible DNMT1-selective inhibitor, with an IC50 of 0.036 μM. GSK-3685032 induces robust loss of DNA methylation, transcriptional activation, and cancer cell growth inhibition. GSK-3685032 Chemical Structure
  20. GC36195 GSK-J1 lithium salt GSK-J1 lithium salt is a potent inhibitor of H3K27me3/me2-demethylases JMJD3/KDM6B and UTX/KDM6A, with IC50 of 60 nM towards KDM6B. GSK-J1 lithium salt Chemical Structure
  21. GC43792 GSK-J2 (sodium salt) The histone H3 lysine 27 (H3K27) demethylase JMJD3 plays important roles in the transcriptional regulation of cell differentiation, development, the inflammatory response, and cancer. GSK-J2 (sodium salt) Chemical Structure
  22. GC43794 GSK-J5 (hydrochloride) The histone H3 lysine 27 (H3K27) demethylase JMJD3 plays important roles in the transcriptional regulation of cell differentiation, development, the inflammatory response, and cancer. GSK-J5 (hydrochloride) Chemical Structure
  23. GC18012 GSK-LSD1 (hydrochloride) LSD1 inhibitor GSK-LSD1 (hydrochloride) Chemical Structure
  24. GC15368 GSK-LSD1 2HCl irreversible, and selective LSD1 inhibitor GSK-LSD1 2HCl Chemical Structure
  25. GC32764 GSK-LSD1 Dihydrochloride An LSD1 inhibitor GSK-LSD1 Dihydrochloride Chemical Structure
  26. GC43787 GSK106 (hydrochloride) GSK106 (hydrochloride) is an inactive control for the selective PAD4 inhibitors, GSK484 and GSK199. GSK106 (hydrochloride) Chemical Structure
  27. GC10008 GSK1070916 A potent inhibitor of Aurora B and C kinases GSK1070916 Chemical Structure
  28. GC43788 GSK121 (trifluoroacetate salt) GSK-121 Trifluoroacetates a selective PAD4 inhibitor. GSK121 (trifluoroacetate salt) Chemical Structure
  29. GC15783 GSK126

    A selective EZH2 inhibitor

     GSK126 Chemical Structure
  30. GC14063 GSK1324726A BET proteins inhibitor GSK1324726A Chemical Structure
  31. GC43789 GSK199 (hydrochloride) GSK199 (hydrochloride) is a reversible and selective PAD4 inhibitor with an IC50 of 200 nM in the absence of calcium. GSK199 (hydrochloride) Chemical Structure
  32. GC15789 GSK2801 inhibitor of BAZ2A and BAZ2B bromodomains GSK2801 Chemical Structure
  33. GC19181 GSK2807 Trifluoroacetate GSK2807 Trifluoroacetate is a potent, selective and SAM-competitive inhibitor of SMYD3, with a Ki of 14 nM. GSK2807 Trifluoroacetate Chemical Structure
  34. GC11578 GSK2879552 Novel and irreversible LSD1 inhibitor GSK2879552 Chemical Structure
  35. GC62719 GSK2879552 dihydrochloride GSK2879552 dihydrochloride an orally active, selective and irreversible inhibitor of lysine specific demethylase 1 (LSD1/KDM1A), with potential antineoplastic activity. GSK2879552 dihydrochloride Chemical Structure
  36. GC18402 GSK3117391 GSK3117391 is a histone deacetylase (HDAC) inhibitor, extracted from patent WO/2008040934 A1. GSK3117391 Chemical Structure
  37. GC32693 GSK3326595 (EPZ015938) GSK3326595 (EPZ015938) (EPZ015938) is a potent, selective, reversible inhibitor of protein arginine methyltransferase 5 (PRMT5) with an IC50 of 6.2 nM. GSK3326595 (EPZ015938) Chemical Structure
  38. GC36191 GSK3368715 GSK3368715 (EPZ019997) is an orally active, reversible, and S-adenosyl-L-methionine (SAM) uncompetitive type I protein arginine methyltransferases (PRMTs) inhibitor (IC50=3.1 nM (PRMT1), 48 nM (PRMT3), 1148 nM (PRMT4), 5.7 nM (PRMT6), 1.7 nM (PRMT8)). GSK3368715 (EPZ019997) produces a shift in arginine methylation states, alters exon usage, and has strong anti-cancer activity. GSK3368715 Chemical Structure
  39. GC25483 GSK3368715 (EPZ019997) 3HCl GSK3368715 is a potent inhibitor of type I protein arginine methyltransferases (PRMT) that inhibits PRMT1, 3, 4, 6 and 8 with Kiapp vaules ranging from 1.5 to 81 nM. GSK3368715 (EPZ019997) 3HCl Chemical Structure
  40. GC49398 GSK3368715 (hydrochloride) An inhibitor of type I PRMTs GSK3368715 (hydrochloride) Chemical Structure
  41. GC36192 GSK3368715 dihydrochloride GSK3368715 dihydrochloride (EPZ019997 dihydrochloride) is an orally active, reversible, and S-adenosyl-L-methionine (SAM) uncompetitive type I protein arginine methyltransferases (PRMTs) inhibitor (IC50=3.1 nM (PRMT1), 48 nM (PRMT3), 1148 nM (PRMT4), 5.7 nM (PRMT6), 1.7 nM (PRMT8)). GSK3368715 dihydrochloride (EPZ019997 dihydrochloride) produces a shift in arginine methylation states, alters exon usage, and has strong anti-cancer activity. GSK3368715 dihydrochloride Chemical Structure
  42. GC17534 GSK343 A selective, cell-permeable EZH2 inhibitor GSK343 Chemical Structure
  43. GC30714 GSK4028 GSK4028 is the enantiomeric negative control of GSK4027, which is a PCAF/GCN5 bromodomain chemical probe, the pIC50 of GSK4028 is 4.9 in a time-resolved fluorescence resonance energy transfer (TR-FRET) assay. GSK4028 Chemical Structure
  44. GC34604 GSK467 GSK467 is a cell penetrant and selective KDM5B (JARID1B or PLU1) inhibitor with a Ki of 10 nM and an IC50 of 26 nM. GSK467 shows 180-fold selectivity for KDM4C and no measurable inhibitory effects toward KDM6 or other Jumonji family members. GSK467 Chemical Structure
  45. GC19184 GSK484 hydrochloride

    GSK484 is a selective PAD4 inhibitor with an IC50 of 50 nM without calcium.

     GSK484 hydrochloride Chemical Structure
  46. GC11414 GSK503 EZH2 inhibitor GSK503 Chemical Structure
  47. GC14585 GSK591 PRMT5 inhibitor GSK591 Chemical Structure
  48. GC62312 GSK620 GSK620 is a potent and orally active pan-BD2 inhibitor with excellent broad selectivity, developability and in vivo oral pharmacokinetics. GSK620 Chemical Structure
  49. GC13025 GSK6853 BRPF1 inhibitor GSK6853 Chemical Structure
  50. GC62654 GSK778 GSK778 (iBET-BD1) is a potent and selective BD1 bromodomain inhibitor of the BET proteins, with IC50s of 75 nM (BRD2 BD1), 41 nM (BRD3 BD1), 41 nM (BRD4 BD1), and 143 nM (BRDT BD1), respectively. GSK778 Chemical Structure
  51. GC38049 GSK8573 GSK8573 is an inactive control compound for GSK2801 (acetyl-lysine competitive inhibitor of BAZ2A and BAZ2B bromodomains). GSK8573 has binding activity to BRD9 with a Kd value of 1.04 μM and is inactive against BAZ2A/B and other bromodomain familiy. GSK8573 can be used as a structurally related negative control compound in biological experiments. GSK8573 Chemical Structure
  52. GC60184 GSK8814 GSK8814 is a potent, selective, and ATAD2/2B bromodomain chemical probe and inhibitor, with a binding constant pKd=8.1 and a pKi=8.9 in BROMOscan. GSK8814 binds to ATAD2 and BRD4 BD1 with pIC50s of 7.3 and 4.6, respectively. GSK8814 shows 500-fold selectivity for ATAD2 over BRD4 BD1. GSK8814 Chemical Structure
  53. GC33324 GSK9311 GSK9311, a less active analogue of GSK6853, can be used as a negative control. GSK9311 inhibits BRPF bromodomain with pIC50 values of 6.0 and 4.3 for BRPF1 and BRPF2, respectively. GSK9311 Chemical Structure
  54. GC36196 Guadecitabine sodium Guadecitabine is a novel hypomethylating dinucleotide of decitabine and deoxyguanosine that is resistant to degradation by cytidine deaminase. Guadecitabine sodium Chemical Structure
  55. GC33041 Gusacitinib (ASN-002) Gusacitinib (ASN-002) (ASN-002) is an orally active and potent dual inhibitor of spleen tyrosine kinase (SYK) and janus kinase (JAK) with IC50 values of 5-46 nM. Gusacitinib (ASN-002) has anti-cancer activity in both solid and hematological tumor types. Gusacitinib (ASN-002) Chemical Structure
  56. GC16611 GW841819X

    BET bromodomain inhibitor

     GW841819X Chemical Structure
  57. GC64115 Gypenoside LI Gypenoside LI, a gypenoside monomer, possesses anti-tumor activity. Gypenoside LI induces cell apoptosis, cell cycle and migration. Gypenoside LI Chemical Structure
  58. GC12009 HAT Inhibitor II HAT Inhibitor II (compound 2c) is a potent, selective and cell permeable p300 histone acetyltransferase inhibitor, with an IC50 of 5 μM. HAT Inhibitor II shows anti-acetylase activity in mammalian cells. HAT Inhibitor II Chemical Structure
  59. GC33422 HAT-IN-1 HAT-IN-1 is an inhibitor of HAT, used in the research of cancer. HAT-IN-1 Chemical Structure
  60. GC43806 HC Toxin HC Toxin is a cell-permeable, reversible inhibitor of histone deacetylases (HDACs) (IC50 = 30 nM). HC Toxin Chemical Structure
  61. GC19190 HDAC-IN-4 HDAC-IN-4 is a potent, selective and orally active class I HDAC inhibitor with IC50s of 63 nM, 570 nM and 550 nM for HDAC1, HDAC2 and HDAC3, respectively. HDAC-IN-4 has no activity against HDAC class II. HDAC-IN-4 has antitumor activity. HDAC-IN-4 Chemical Structure
  62. GC66052 HDAC-IN-40 HDAC-IN-40 is a potent alkoxyamide-based HDAC inhibitor with Ki values of 60 nM and 30 nM for HDAC2 and HDAC6, respectively. HDAC-IN-40 had antitumor effects. HDAC-IN-40 Chemical Structure
  63. GC33395 HDAC-IN-5 HDAC-IN-5 is a histone deacetylase (HDAC) inhibitor. HDAC-IN-5 Chemical Structure
  64. GC41495 HDAC3 Inhibitor HDAC3 Inhibitor (compound 5) is a potent and selective HDAC3 inhibitor, with an IC50 of 5.96 nM. HDAC3 Inhibitor Chemical Structure
  65. GC68010 HDAC3-IN-T247 HDAC3-IN-T247 Chemical Structure
  66. GC49693 HDAC5 (human, recombinant) Active, pure human recombinant enzyme HDAC5 (human, recombinant) Chemical Structure
  67. GC41085 HDAC6 Inhibitor HDAC6 Inhibitor is a potent and selective HDAC6 inhibitor (IC50=36 nM). HDAC6 Inhibitor weakly inhibits other HDAC isoforms. HDAC6 Inhibitor inhibits acyl-tubulin accumulation in cells with an IC50 value of 210 nM. HDAC6 Inhibitor Chemical Structure
  68. GC33317 HDAC6-IN-1 HDAC6-IN-1 is a potent and selective inhibitor for HDAC6 with an IC50 of 17 nM and shows 25-fold and 200-fold selectivity relative to HDAC1 (IC50=422 nM) and HDAC8 (IC50=3398 nM), respectively. HDAC6-IN-1 Chemical Structure
  69. GC19189 HDAC8-IN-1 HDAC8-IN-1 is a HDAC8 inhibitor with an IC50 of 27.2 nM. HDAC8-IN-1 Chemical Structure
  70. GC65460 HDACs/mTOR Inhibitor 1 HDACs/mTOR Inhibitor 1 is a dual Histone Deacetylases (HDACs) and mammalian target of Rapamycin (mTOR) target inhibitor for treating hematologic malignancies, with IC50s of 0.19 nM, 1.8 nM, 1.2 nM and >500 nM for HDAC1, HDAC6, mTOR and PI3Kα, respectively. HDACs/mTOR Inhibitor 1 stimulates cell cycle arrest in G0/G1 phase and induce tumor cell apoptosis with low toxicity in vivo. HDACs/mTOR Inhibitor 1 Chemical Structure
  71. GC17196 Hesperadin A multi-kinase inhibitor Hesperadin Chemical Structure
  72. GC50050 Hesperadin hydrochloride Potent Aurora kinase B inhibitor Hesperadin hydrochloride Chemical Structure
  73. GC39146 HIF-1 inhibitor-1 An inhibitor of HIF-1 signaling HIF-1 inhibitor-1 Chemical Structure
  74. GC66464 HIF-1α-IN-2 HIF-1α-IN-2 is an effective HIF-1α inhibitor with anticancer potencies (IC50s of 28 nM and 15 nM in MDA-MB-231 and MiaPaCa-2 cells, respectively). HIF-1α-IN-2 suppresses HIF-1α expression by blocking transcription and protein translation. HIF-1α-IN-2 Chemical Structure
  75. GC62584 HIF-2α-IN-2 HIF-2α-IN-2 is a hypoxia-inducible factors (HIF-2α) inhibitor extracted from patent WO2015035223A1, Compound 232, has an IC50 of 16 nM in scintillation proximity assay (SPA). HIF-2α-IN-2 Chemical Structure
  76. GC62418 HIF-2α-IN-3 HIF-2α-IN-3, an allosteric inhibitor of hypoxia inducible factor-2α (HIF-2α), exhibits an IC50 of 0.4 μM and a KD of 1.1 μM. Anticancer agent. HIF-2α-IN-3 Chemical Structure
  77. GC63678 HIF-2α-IN-4 HIF-2α-IN-4 is a potent inhibitor of hypoxia inducible factor-2α (HIF-2α) translation, with an IC50 of 5 μM. HIF-2α-IN-4 decreases both constitutive and hypoxia-induced HIF-2α protein expression. HIF-2α-IN-4 links its 5'UTR iron-responsive element to oxygen sensing. HIF-2α-IN-4 Chemical Structure
  78. GC31358 HIF-2α-IN-1 HIF-2α-IN-1 is a HIF-2α inhibitor has an IC50 of less than 500 nM in HIF-2α scintillation proximity assay. HIF-2α-IN-1 Chemical Structure
  79. GC67941 HIF-PHD-IN-1 HIF-PHD-IN-1 Chemical Structure
  80. GC65570 HIF1-IN-3 HIF1-IN-3 (compound F4) is a potent HIF1 inhibitor with an EC50 value of 0.9 μM. HIF1-IN-3 can be used for researching anticancer. HIF1-IN-3 Chemical Structure
  81. GC11302 Hinokitiol A tropolone with diverse biological activities Hinokitiol Chemical Structure
  82. GC12359 Hispidulin Partial positive allosteric modulator at the benzodiazepine receptor Hispidulin Chemical Structure
  83. GC43831 Histone H3 (21-44)-GK-biotin (trifluoroacetate salt) Histone H3 (21-44)-GK-biotin is a peptide fragment of histone H3 that corresponds to amino acid residues 22-45 of the human histone H3.1 and 3.2 sequences and is biotinylated via a C-terminal GK linker. Histone H3 (21-44)-GK-biotin (trifluoroacetate salt) Chemical Structure
  84. GC43832 Histone H3 (21-44)-GK-biotin amide (trifluoroacetate salt) Histone H3 (21-44)-GK-biotin is a peptide fragment of histone H3 that corresponds to amino acid residues 22-45 of the human histone H3.3 sequence and is biotinylated via a C-terminal GK linker. Histone H3 (21-44)-GK-biotin amide (trifluoroacetate salt) Chemical Structure
  85. GC52479 Histone H3 (Citrullinated R26) (21-44)-GGK-biotin Peptide (trifluoroacetate salt) A biotinylated peptide fragment of histone H3 Histone H3 (Citrullinated R26) (21-44)-GGK-biotin Peptide (trifluoroacetate salt) Chemical Structure
  86. GC43846 Histone H3K27Me1 (23-34) (trifluoroacetate salt) Histone H3K27Me1 (23-34) is a peptide fragment of histone H3 that corresponds to amino acid residues 24-35 of the human histone H3.1 and H3.2 sequences. Histone H3K27Me1 (23-34) (trifluoroacetate salt) Chemical Structure
  87. GP10020 Histone-H2A-(107-122)-Ac-OH

    Histone-H2A peptide

     Histone-H2A-(107-122)-Ac-OH Chemical Structure
  88. GC33211 HJB97 HJB97 is a high-affinity BET inhibitor with Kis of 0.9 nM (BRD2 BD1), 0.27 nM (BRD2 BD2), 0.18 nM (BRD3 BD1), 0.21 nM (BRD3 BD2), 0.5 nM (BRD4 BD1), 1.0 nM (BRD4 BD2), respectively. HJB97 is employed for the design of potential PROTAC BET degrader and has antitumor activity. HJB97 Chemical Structure
  89. GC17023 HLCL-61 HLCL-61 is a first-in-class inhibitor of protein arginine methyltransferase 5 (PRMT5). HLCL-61 Chemical Structure
  90. GC12334 HNHA HDAC inhibitor HNHA Chemical Structure
  91. GC11574 HPOB HDAC6 inhibitor, potent and selective HPOB Chemical Structure
  92. GC11767 Hydralazine HCl Hydralazine HCl is a orally active antihypertensive agent, reduces peripheral resistance directly by relaxing the smooth muscle cell layer in arterial vessel. Hydralazine HCl Chemical Structure
  93. GC60919 Hydroxycitric acid tripotassium hydrate Hydroxycitric acid tripotassium hydrate (Potassium citrate monohydrate) is the major active ingredient of Garcinia cambogia. Hydroxycitric acid tripotassium hydrate Chemical Structure
  94. GC50070 I-BET 151 dihydrochloride BET bromodomain inhibitor; also promotes differentiation of hiPSCs into megakaryocytes I-BET 151 dihydrochloride Chemical Structure
  95. GC13187 I-BET 151 hydrochloride BET bromodomain inhibitor I-BET 151 hydrochloride Chemical Structure
  96. GC17073 I-BET-762 I-BET-762 (I-BET762; GSK525762) is a BET bromodomain inhibitor with IC50 of 32.5-42.5 nM. I-BET-762 Chemical Structure
  97. GC15747 I-BET151 (GSK1210151A) I-BET151 (GSK1210151A) (GSK1210151A) is a BET bromodomain inhibitor which inhibits BRD4, BRD2, and BRD3 with pIC50 of 6.1, 6.3, and 6.6, respectively. I-BET151 (GSK1210151A) Chemical Structure
  98. GC64297 I-BET567 I-BET567 is a potent and orally active inhibitor of pan-BET candidate with pIC50s of 6.9 and 7.2 for BRD4 BD1 and BD2, respectively. I-BET567 Chemical Structure
  99. GC12588 I-BRD9 BRD9 inhibitor I-BRD9 Chemical Structure
  100. GC17944 I-CBP 112 A p300 and CBP inhibitor I-CBP 112 Chemical Structure
  101. GC34078 I-CBP112 I-CBP112 is a specific and potent acetyl-lysine competitive protein-protein interaction inhibitor, that inhibits the CBP/p300 bromodomains, enhances acetylation by p300. I-CBP112 Chemical Structure

Items 501 to 600 of 1279 total

per page
  2. 4
  3. 5
  4. 6
  5. 7
  6. 8

Set Descending Direction